{"id":16138,"date":"2026-06-08T15:50:29","date_gmt":"2026-06-08T08:50:29","guid":{"rendered":"https:\/\/vinphaco.net\/?p=16138"},"modified":"2026-06-08T15:54:52","modified_gmt":"2026-06-08T08:54:52","slug":"gina-2026-asthma-guidelines","status":"publish","type":"post","link":"https:\/\/vinphaco.net\/es\/gina-2026-asthma-guidelines\/","title":{"rendered":"GINA 2026 Asthma Guidelines: 10 Important Updates Transforming Asthma Management"},"content":{"rendered":"

GINA 2026 Asthma Guidelines: 10 Important Updates Transforming Asthma Management<\/h2>\n

The GINA 2026 Asthma Guidelines introduce several important changes in asthma diagnosis, treatment strategies, acute exacerbation management and biologic therapies. These updates aim to improve patient safety, reduce severe asthma attacks and strengthen evidence-based clinical practice worldwide.<\/p>\n

Asthma affects approximately 300 million people globally and contributes to nearly 1,000 deaths every day. According to the Global Initiative for Asthma (GINA), many of these deaths are preventable through timely diagnosis, appropriate anti-inflammatory treatment and improved disease management.<\/p>\n

Table of Contents<\/strong><\/p>\n

    \n
  1. Overview of the GINA 2026 Asthma Guidelines<\/strong><\/li>\n
  2. Updates in Asthma Diagnosis<\/strong><\/li>\n
  3. Changes in Reliever and Maintenance Therapy<\/strong><\/li>\n
  4. Acute Asthma Exacerbation Management<\/strong><\/li>\n
  5. New Biologic Therapies for Severe Asthma<\/strong><\/li>\n
  6. RSV Prevention and Future Directions<\/strong><\/li>\n
  7. Key Takeaways for Healthcare Professionals<\/strong><\/li>\n<\/ol>\n

    Overview of the GINA 2026 Asthma Guidelines<\/h3>\n

    The GINA 2026 Asthma Guidelines continue the organization’s commitment to improving asthma outcomes through evidence-based recommendations. The latest report places greater emphasis on patient safety, individualized treatment approaches and anti-inflammatory reliever strategies.<\/p>\n

    Several important updates focus on reducing the risk of severe exacerbations while improving treatment adherence and long-term disease control.<\/p>\n

    GINA 2026 Asthma Guidelines \u2013 Updates in Diagnosis<\/h3>\n

    GINA continues to recommend the traditional bronchodilator responsiveness (BDR) criterion for asthma diagnosis in adults and children aged six years and older.<\/p>\n

    A positive bronchodilator response is defined as:<\/p>\n

    \u2022 Increase in FEV1 or FVC \u226512%
    \n\u2022 Increase of at least 200 mL after bronchodilator administration<\/p>\n

    The updated guidelines also introduce new assessment tools that support more personalized patient management.<\/p>\n

    CAAT (Chronic Airways Assessment Test)<\/p>\n

    The CAAT questionnaire includes eight patient-centered questions designed to evaluate chronic airway health in both asthma and COPD patients.<\/p>\n

    Peds-AIRQ<\/p>\n

    This assessment tool is intended for children aged 5\u201311 years and evaluates symptom control as well as future exacerbation risk.<\/p>\n

    PRAM<\/p>\n

    GINA strongly recommends the Pediatric Respiratory Assessment Measure (PRAM) as an objective method for evaluating acute asthma severity in pediatric patients.\"GINA<\/p>\n

    GINA 2026 Asthma Guidelines \u2013 Changes in Reliever and Maintenance Therapy<\/h3>\n

    One of the most significant updates in the GINA 2026 Asthma Guidelines involves treatment strategies.<\/p>\n

    Track 1 \u2013 Preferred Pathway<\/p>\n

    As-needed low-dose ICS-formoterol remains the preferred reliever option for adults and adolescents.<\/p>\n

    This approach:<\/p>\n

    \u2022 Reduces severe exacerbation risk
    \n\u2022 Improves adherence
    \n\u2022 Simplifies inhaler use across treatment steps<\/p>\n

    Track 2 \u2013 Alternative Pathway<\/p>\n

    Based on findings from the BATURA study, GINA has incorporated ICS-SABA combination therapy into Step 1.<\/p>\n

    Compared with SABA-only treatment, ICS-SABA therapy significantly lowers the risk of severe asthma exacerbations.<\/p>\n

    Triple Therapy in Step 5<\/p>\n

    For patients aged 12 years and older whose asthma remains uncontrolled despite optimized medium- or high-dose ICS-LABA treatment, triple therapy using ICS-LABA-LAMA combinations may be considered.<\/p>\n

    GINA 2026 Asthma Guidelines for Acute Asthma Exacerbation Management<\/h3>\n

    Acute asthma management receives substantial attention in the updated report.<\/p>\n

    New Emergency Algorithms<\/p>\n

    GINA introduces four dedicated management pathways that differentiate:<\/p>\n

    \u2022 Primary care settings
    \n\u2022 Emergency departments
    \n\u2022 Children under 5 years
    \n\u2022 Patients aged 6 years and older<\/p>\n

    Exacerbations are classified into:<\/p>\n

    \u2022 Mild
    \n\u2022 Moderate
    \n\u2022 Severe
    \n\u2022 Life-threatening<\/p>\n

    Updated Oxygen Targets<\/p>\n

    Supplemental oxygen is recommended only when oxygen saturation falls below 92%.<\/p>\n

    Target oxygen saturation should generally not exceed:<\/p>\n

    \u2022 95% in adults and children aged 6 years and above
    \n\u2022 92% in children under 5 years<\/p>\n

    Safer SABA Dosing<\/p>\n

    GINA highlights the risk of excessive SABA use, which may contribute to lactic acidosis and diagnostic confusion.<\/p>\n

    Recommended doses include:<\/p>\n

    \u2022 Mild exacerbation: 4 inhalations
    \n\u2022 Moderate exacerbation: 4\u20136 inhalations<\/p>\n

    Use of ICS-Formoterol in the Emergency Department<\/p>\n

    For mild acute asthma attacks, ICS-formoterol may be used as a reliever instead of SABA, allowing earlier anti-inflammatory intervention.<\/p>\n

    New Biologic Therapies for Severe Asthma<\/h3>\n

    The GINA 2026 Asthma Guidelines expand treatment options for severe asthma.<\/p>\n

    Depemokimab<\/p>\n

    Depemokimab is a long-acting anti-IL-5 biologic administered every 26 weeks for patients aged 12 years and older with eosinophilic asthma.<\/p>\n

    Omalizumab Biosimilar<\/p>\n

    The report also includes omalizumab-igec, a biosimilar anti-IgE therapy, as a treatment option for eligible patients.<\/p>\n

    The updated guidance encourages clinicians to consider comorbidities such as:<\/p>\n

    \u2022 Atopic dermatitis
    \n\u2022 Nasal polyps
    \n\u2022 Chronic urticaria<\/p>\n

    when selecting biologic therapies.<\/p>\n

    RSV Prevention and Future Directions<\/h3>\n

    Respiratory syncytial virus (RSV) remains a leading cause of wheezing and lower respiratory tract infections in infants.<\/p>\n

    The GINA 2026 Asthma Guidelines highlight emerging evidence supporting:<\/p>\n

    \u2022 Maternal RSV vaccination during pregnancy
    \n\u2022 Nirsevimab administration in infants<\/p>\n

    These preventive measures may help reduce the burden of RSV-associated disease and potentially lower future asthma risk.<\/p>\n

    Key Takeaways for Healthcare Professionals<\/h3>\n

    The GINA 2026 Asthma Guidelines represent a major step forward in asthma care.<\/p>\n

    Key themes include:<\/p>\n

    \u2022 Greater emphasis on anti-inflammatory reliever therapy
    \n\u2022 More cautious SABA use
    \n\u2022 Lower oxygen targets
    \n\u2022 Expanded biologic treatment options
    \n\u2022 Improved pediatric assessment tools
    \n\u2022 Stronger focus on patient safety<\/p>\n

    Healthcare professionals should familiarize themselves with these recommendations to optimize asthma outcomes and reduce the burden of severe exacerbations.<\/p>\n

    \"GINA<\/p>\n

    References<\/p>\n

    Global Initiative for Asthma (GINA)<\/p>\n

    https:\/\/ginasthma.org\/2026-gina-strategy-report\/<\/a><\/p>\n

    World Health Organization (WHO)<\/p>\n

    https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma<\/a><\/p>\n

    About Vinphaco<\/a><\/p>\n

    Vinphaco is a WHO-GMP certified pharmaceutical manufacturer in Vietnam supplying injectable products, ophthalmic products, oral solid dosage forms and other healthcare solutions to international markets across Asia, Africa, the Middle East and Latin America.<\/p>\n

    For partnership opportunities, CTD dossiers or contract manufacturing inquiries, please contact our Export Department.<\/p>\n","protected":false},"excerpt":{"rendered":"

    GINA 2026 Asthma Guidelines: 10 Important Updates Transforming Asthma Management The GINA 2026 Asthma Guidelines introduce several important changes in asthma diagnosis, treatment strategies, acute exacerbation management and biologic therapies. These updates aim to improve patient safety, reduce severe asthma attacks and strengthen evidence-based clinical practice worldwide. Asthma affects approximately 300 million people globally and…<\/p>\n","protected":false},"author":5,"featured_media":16167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[1201],"class_list":["post-16138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-information","tag-gina-2026-asthma-asthma-management-ics-formoterol-severe-asthma-respiratory-care-pulmonology-clinical-pharmacy"],"acf":[],"_links":{"self":[{"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/posts\/16138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/comments?post=16138"}],"version-history":[{"count":1,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/posts\/16138\/revisions"}],"predecessor-version":[{"id":16175,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/posts\/16138\/revisions\/16175"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/media\/16167"}],"wp:attachment":[{"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/media?parent=16138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/categories?post=16138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vinphaco.net\/es\/wp-json\/wp\/v2\/tags?post=16138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}